Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDI Notifications Are Not Swept Aside As New Drugs – FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA’s rejection of PharmaRoth Labs’ Sucanon NDI notifications included a suggestion that the firm try the investigational new drug pathway, but is not a sign of a growing trend at the agency.


Related Content

FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts